600276.SS in “China Becomes Pharma's Global R&D Engine”
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
One of China's deepest drug pipelines gives Hengrui a growing inventory of assets that can be licensed to global partners.
600276.SS impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 600276.SS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 600276.SS impact map…
Price history, marked with story events
Oct 13, 2025 – Oct 12, 2026 · 245 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — One of China's deepest drug pipelines gives Hengrui a growing inventory of assets that can be licensed to global partners.
Read the full China Becomes Pharma's Global R&D Engine story